ACell, Inc. today announced that it has appointed Thomas Gilbert, Ph.D., as Chief Science Officer. Dr. Gilbert has served as Vice President, Research and Development at ACell since 2012.
“Dr. Gilbert is a highly-regarded expert in extracellular matrices and regenerative medicine” said James A. D’Orta, MD, Chief Executive Officer. “He has already played a key role in expanding ACell’s Research and Development capabilities and advancing new discoveries related to our technology portfolio. His insights and depth of experience will be instrumental in our company’s continued growth.”
In his new position, Dr. Gilbert will add oversight of Clinical Research programs to his Research and Development responsibilities, with the goal of building a unified product development strategy from initial concept to post-market clinical evaluation.
“There is profound potential to address a variety of clinical needs through ACell’s proprietary technology,” said Dr. Gilbert. “I am excited to continue advancing our efforts to transform the standards of medical care and improve patient quality of life.”
Dr. Gilbert previously served as Assistant Professor of Surgery, Cardiothoracic Surgery, and Bioengineering at the University of Pittsburgh and was a faculty member of the McGowan Institute for Regenerative Medicine. His research includes the study of processing and use of extracellular matrix scaffold materials (including urinary bladder matrix) for development of regenerative medicine strategies in a variety of body systems.
About ACell, Inc.
ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing and commercialization of unique proprietary extracellular matrix (ECM) products to facilitate the repair and remodeling of damaged tissues. ACell is committed to becoming and remaining an innovative leader in regenerative medical technology, offering superior healing options for doctors and patients. ACell is a privately held company and operates manufacturing facilities in Columbia, MD and Lafayette, IN. For more information, call 800-826-2926 or visit www.acell.com.
MatriStem products contain the epithelial basement membrane from porcine urinary bladder, and are based on the proprietary ECM composition generally referred to in scientific literature as urinary bladder matrix, or UBM. UBM is a segment of tissue layers that facilitates a constructive tissue remodeling response by the patient’s body. MatriStem products are indicated for use in general surgery, gynecological surgery, and in the management of a wide range of wounds. Refer to the IFU supplied with each product for indications, contraindications and precautions. All MatriStem products are made in the USA.Return to News